Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.

Richard W. Joseph,Jeanette E. Eckel Passow,Ruchi G. Sharma,Ping Liu,Alexander S. Parker,John Jakob,Elizabeth I. Buchbinder,Roland L. Bassett,Michael A. Davies,Patrick Hwu,Michael B. Atkins,Ryan J. Sullivan

Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.

2012

Richard W. Joseph
Jeanette E. Eckel Passow
Ruchi G. Sharma
Ping Liu
Alexander S. Parker
John Jakob
Elizabeth I. Buchbinder
Roland L. Bassett
Michael A. Davies
Patrick Hwu
Michael B. Atkins
Ryan J. Sullivan

Ipilimumab improves overall survival (OS) in patients with metastatic melanoma including those previously treated with high-dose interleukin-2 (HD IL-2). The primary objective of this study was to determine if clinical response or progression-free survival (PFS) to HD IL-2 could predict benefit to s

Keywords:

Melanoma
Ipilimumab
Immunology
Immunotherapy
Biology
Oncology
in patient
Cancer
previously treated
Response rate (survey)
Internal medicine
Progressive disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations